|
MechanismHMG-CoA reductase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date26 Aug 2013 |
|
MechanismAT III activators |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date07 Dec 2001 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date27 Aug 1997 |
100 Clinical Results associated with Viatris Healthcare (Pty) Ltd.
0 Patents (Medical) associated with Viatris Healthcare (Pty) Ltd.
100 Deals associated with Viatris Healthcare (Pty) Ltd.
100 Translational Medicine associated with Viatris Healthcare (Pty) Ltd.